skip to main content
Idioma:
Refinado por: data de publicação: Após 2010 remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
0147 Dynamic Alterations in Functional Connectivity Between Sleep- and Wake-Promoting Regions of the Human Brain at the Sleep Onset Period
0147 Dynamic Alterations in Functional Connectivity Between Sleep- and Wake-Promoting Regions of the Human Brain at the Sleep Onset Period
Material Type:
Artigo 		Adicionar ao Meu Espaço

0147 Dynamic Alterations in Functional Connectivity Between Sleep- and Wake-Promoting Regions of the Human Brain at the Sleep Onset Period

Ishii, T ; Koike, T ; Nakagawa, E ; Sumiya, M ; Sadato, N

Sleep (New York, N.Y.), 2020-05, Vol.43 (Supplement_1), p.A58-A58 [Periódico revisado por pares]

US: Oxford University Press

Texto completo disponível

Citações Citado por
2
1-Deoxynojirimycin attenuates high glucose-accelerated senescence in human umbilical vein endothelial cells
1-Deoxynojirimycin attenuates high glucose-accelerated senescence in human umbilical vein endothelial cells
Material Type:
Artigo 		Adicionar ao Meu Espaço

1-Deoxynojirimycin attenuates high glucose-accelerated senescence in human umbilical vein endothelial cells

E., Shuang ; Kijima, Ryo ; Honma, Taro ; Yamamoto, Kazushi ; Hatakeyama, Yu ; Kitano, Yasuna ; Kimura, Toshiyuki ; Nakagawa, Kiyotaka ; Miyazawa, Teruo ; Tsuduki, Tsuyoshi

Experimental gerontology, 2014-07, Vol.55, p.63-69 [Periódico revisado por pares]

England: Elsevier Inc

Texto completo disponível

Citações Citado por
3
1013 IMPACT OF NEWLY DEVELOPED HIGH-SENSITIVE (I-FETOPROTEIN-L3 FRACTION ASSAY ON THE DIAGNOSIS AND TREATMENT EVALUATION OF HEPATOCELLULAR CARCINOMA
1013 IMPACT OF NEWLY DEVELOPED HIGH-SENSITIVE (I-FETOPROTEIN-L3 FRACTION ASSAY ON THE DIAGNOSIS AND TREATMENT EVALUATION OF HEPATOCELLULAR CARCINOMA
Material Type:
Artigo 		Adicionar ao Meu Espaço

1013 IMPACT OF NEWLY DEVELOPED HIGH-SENSITIVE (I-FETOPROTEIN-L3 FRACTION ASSAY ON THE DIAGNOSIS AND TREATMENT EVALUATION OF HEPATOCELLULAR CARCINOMA

Tateishi, R ; Nakagawa, H ; Shiina, S ; Enooku, K ; Mikami, S ; Sato, M ; Uchino, K ; Arano, T ; Masuzaki, R ; Goto, E ; Kondo, Y ; Goto, T ; Fujie, H ; Ikeda, H ; Omata, M ; Yoshida, H ; Koike, K

Journal of hepatology, 2011-03, Vol.54, p.S403-S403 [Periódico revisado por pares]

Elsevier B.V

Texto completo disponível

Citações Citado por
4
1025P DOcetaxel (DOC) plus RAmucirumab (RAM) with pegylated Granulocyte-colONy stimulating factor (PEG-G-CSF) for elderly patients with advanced non-small cell lung cancer (NSCLC): A phase II trial (DRAGON study: WJOG9416L)
1025P DOcetaxel (DOC) plus RAmucirumab (RAM) with pegylated Granulocyte-colONy stimulating factor (PEG-G-CSF) for elderly patients with advanced non-small cell lung cancer (NSCLC): A phase II trial (DRAGON study: WJOG9416L)
Material Type:
Artigo 		Adicionar ao Meu Espaço

1025P DOcetaxel (DOC) plus RAmucirumab (RAM) with pegylated Granulocyte-colONy stimulating factor (PEG-G-CSF) for elderly patients with advanced non-small cell lung cancer (NSCLC): A phase II trial (DRAGON study: WJOG9416L)

Tokito, T. ; Hata, A. ; Hara, S. ; Tachihara, M. ; Okada, H. ; Tanaka, H. ; Sato, Y. ; Tabata, E. ; Watanabe, H. ; Takayama, Y. ; Toyozawa, R. ; Okamoto, I. ; Wakuda, K. ; Nakamura, A. ; Shimokawa, M. ; Yamamoto, N. ; Nakagawa, K.

Annals of oncology, 2022-09, Vol.33, p.S1023-S1024 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
5
1047 Visceral obesity is a useful predictor of better recurrence-free survival after curative surgeries for Japanese patients with localized clear cell renal cell carcinoma
1047 Visceral obesity is a useful predictor of better recurrence-free survival after curative surgeries for Japanese patients with localized clear cell renal cell carcinoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

1047 Visceral obesity is a useful predictor of better recurrence-free survival after curative surgeries for Japanese patients with localized clear cell renal cell carcinoma

Kaneko, G ; Miyajima, A ; Hasegawa, M ; Mizuno, R ; Uchida, Y ; Hara, S ; Kikuchi, E ; Nakagawa, K ; Jinzaki, M ; Oya, M

European urology supplements : official journal of the European Association of Urology, 2014-04, Vol.13 (1), p.e1047-e1047a

Elsevier B.V

Texto completo disponível

Citações Citado por
6
1109 Does laparoendoscopic single-site adrenalectomy in patients with unilateral pheochromocytoma increase surgical risk? A case control study
1109 Does laparoendoscopic single-site adrenalectomy in patients with unilateral pheochromocytoma increase surgical risk? A case control study
Material Type:
Artigo 		Adicionar ao Meu Espaço

1109 Does laparoendoscopic single-site adrenalectomy in patients with unilateral pheochromocytoma increase surgical risk? A case control study

Maeda, T ; Miyajima, A ; Kikuchi, E ; Hasegawa, M ; Yasumizu, Y ; Kaneko, G ; Kosaka, T ; Nakagawa, K ; Oya, M

European urology supplements : official journal of the European Association of Urology, 2012-02, Vol.11 (1), p.e1109-e1109a

Elsevier B.V

Texto completo disponível

Citações Citado por
7
120-Gb/s PDM 64-QAM transmission over 1,280 km using multi-staged nonlinear compensation in digital coherent receiver
120-Gb/s PDM 64-QAM transmission over 1,280 km using multi-staged nonlinear compensation in digital coherent receiver
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

120-Gb/s PDM 64-QAM transmission over 1,280 km using multi-staged nonlinear compensation in digital coherent receiver

Kobayashi, T ; Sano, A ; Matsuura, A ; Yamazaki, E ; Yoshida, E ; Miyamoto, Y ; Nakagawa, T ; Sakamaki, Y ; Mizuno, T

2011 Optical Fiber Communication Conference and Exposition and the National Fiber Optic Engineers Conference, 2011, p.1-3

IEEE

Texto completo disponível

Citações Citado por
8
1225OOVERALL AND INTRACRANIAL (IC) EFFICACY RESULTS AND TIME TO SYMPTOM DETERIORATION IN PROFILE 1014: 1ST-LINE CRIZOTINIB VS PEMETREXED − PLATINUM CHEMOTHERAPY (PPC) IN PATIENTS (PTS) WITH ADVANCED ALK-POSITIVE NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
1225OOVERALL AND INTRACRANIAL (IC) EFFICACY RESULTS AND TIME TO SYMPTOM DETERIORATION IN PROFILE 1014: 1ST-LINE CRIZOTINIB VS PEMETREXED − PLATINUM CHEMOTHERAPY (PPC) IN PATIENTS (PTS) WITH ADVANCED ALK-POSITIVE NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
Material Type:
Artigo 		Adicionar ao Meu Espaço

1225OOVERALL AND INTRACRANIAL (IC) EFFICACY RESULTS AND TIME TO SYMPTOM DETERIORATION IN PROFILE 1014: 1ST-LINE CRIZOTINIB VS PEMETREXED − PLATINUM CHEMOTHERAPY (PPC) IN PATIENTS (PTS) WITH ADVANCED ALK-POSITIVE NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)

Solomon, B ; Felip, E ; Blackhall, F.H ; Mok, T.S.K ; Kim, D ; Wu, Y ; Nakagawa, K ; Mekhail, T ; Paolini, J ; Usari, T ; Iyer, S ; Reisman, A ; Wilner, K ; Tursi, J ; Cappuzzo, F

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv427-iv427 [Periódico revisado por pares]

Oxford University Press

Texto completo disponível

Citações Citado por
9
1226PDIMPACT OF CRIZOTINIB ON PATIENT-REPORTED SYMPTOMS AND GLOBAL QUALITY OF LIFE (QOL) COMPARED WITH PLATINUM BASED CHEMOTHERAPY IN PHASE III STUDY OF TREATMENT NAïVE ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
1226PDIMPACT OF CRIZOTINIB ON PATIENT-REPORTED SYMPTOMS AND GLOBAL QUALITY OF LIFE (QOL) COMPARED WITH PLATINUM BASED CHEMOTHERAPY IN PHASE III STUDY OF TREATMENT NAïVE ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
Material Type:
Artigo 		Adicionar ao Meu Espaço

1226PDIMPACT OF CRIZOTINIB ON PATIENT-REPORTED SYMPTOMS AND GLOBAL QUALITY OF LIFE (QOL) COMPARED WITH PLATINUM BASED CHEMOTHERAPY IN PHASE III STUDY OF TREATMENT NAïVE ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)

Blackhall, F ; Felip, E ; Cappuzzo, F ; Kim, D.W ; Wu, Y ; Solomon, B ; Nakagawa, K ; Mekhail, T ; Paolini, J ; Usari, T ; Iyer, S ; Reisman, A ; Wilner, K ; Tursi, J ; Mok, T

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv428-iv428 [Periódico revisado por pares]

Oxford University Press

Texto completo disponível

Citações Citado por
10
1294P RELAY, erlotinib plus ramucirumab or placebo in untreated EGFR-mutated metastatic NSCLC: Outcomes by EGFR mutation type
1294P RELAY, erlotinib plus ramucirumab or placebo in untreated EGFR-mutated metastatic NSCLC: Outcomes by EGFR mutation type
Material Type:
Artigo 		Adicionar ao Meu Espaço

1294P RELAY, erlotinib plus ramucirumab or placebo in untreated EGFR-mutated metastatic NSCLC: Outcomes by EGFR mutation type

Nakagawa, K. ; Nadal, E. ; Garon, E.B. ; Nishio, M. ; Seto, T. ; Yamamoto, N. ; Park, K. ; Shih, J-Y. ; Frimodt-Moller, B. ; Zimmermann, A.H. ; Visseren-Grul, C.M. ; Reck, M.

Annals of oncology, 2020-09, Vol.31, p.S838-S838 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Data de Publicação 

De até
Refinar
  1. Antes de2012  (217)
  2. 2012Até2014  (456)
  3. 2015Até2017  (500)
  4. 2018Até2021  (628)
  5. Após 2021  (292)
  6. Mais opções open sub menu

Idioma 

  1. Inglês  (1.901)
  2. Japonês  (316)
  3. Português  (125)
  4. Espanhol  (35)
  5. Alemão  (3)
  6. Norueguês  (3)
  7. Francês  (1)
  8. Mais opções open sub menu

Novas Pesquisas Sugeridas

Ignorar minha busca e procurar por tudo

Deste Autor:

  1. Nakagawa, E
  2. Oquendo, F
  3. Graciano Neto, V
  4. Guessi, M
  5. Oliveira, L

Neste Assunto:

  1. Science & Technology
  2. Life Sciences & Biomedicine
  3. Humans
  4. Physical Sciences
  5. Male

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.